153 related articles for article (PubMed ID: 37651468)
21. Non-viral
Braun T; Pruene A; Darguzyte M; Vom Stein AF; Nguyen PH; Wagner DL; Kath J; Roig-Merino A; Heuser M; Riehm LL; Schneider A; Awerkiew S; Talbot SR; Bleich A; Figueiredo C; Bornhäuser M; Stripecke R
Front Immunol; 2023; 14():1086433. PubMed ID: 37033919
[TBL] [Abstract][Full Text] [Related]
22. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.
Wang H; Tsao ST; Gu M; Fu C; He F; Li X; Zhang M; Li N; Hu HM
J Transl Med; 2022 Dec; 20(1):608. PubMed ID: 36536403
[TBL] [Abstract][Full Text] [Related]
23. Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells.
Prazeres PHDM; Ferreira H; Costa PAC; da Silva W; Alves MT; Padilla M; Thatte A; Santos AK; Lobo AO; Sabino A; Del Puerto HL; Mitchell MJ; Guimaraes PPG
Int J Nanomedicine; 2023; 18():5891-5904. PubMed ID: 37873551
[TBL] [Abstract][Full Text] [Related]
24. CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.
Golubovskaya V; Sienkiewicz J; Sun J; Zhang S; Huang Y; Zhou H; Harto H; Xu S; Berahovich R; Wu L
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686170
[TBL] [Abstract][Full Text] [Related]
25. CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells.
Ranganathan R; Shou P; Ahn S; Sun C; West J; Savoldo B; Dotti G
Clin Cancer Res; 2021 Nov; 27(21):5951-5960. PubMed ID: 33858858
[TBL] [Abstract][Full Text] [Related]
26. Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies.
Ying Z; He T; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Wu M; Feng F; Leng X; Du T; Qi F; Hu X; Ding Y; Lu XA; Song Y; Zhu J
BMC Cancer; 2021 Feb; 21(1):198. PubMed ID: 33632155
[TBL] [Abstract][Full Text] [Related]
27. Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering.
Kitte R; Rabel M; Geczy R; Park S; Fricke S; Koehl U; Tretbar US
Mol Ther Methods Clin Dev; 2023 Dec; 31():101139. PubMed ID: 38027056
[TBL] [Abstract][Full Text] [Related]
28. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.
Michels KR; Sheih A; Hernandez SA; Brandes AH; Parrilla D; Irwin B; Perez AM; Ting HA; Nicolai CJ; Gervascio T; Shin S; Pankau MD; Muhonen M; Freeman J; Gould S; Getto R; Larson RP; Ryu BY; Scharenberg AM; Sullivan AM; Green S
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918221
[TBL] [Abstract][Full Text] [Related]
29. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.
Tsukahara T; Ohmine K; Yamamoto C; Uchibori R; Ido H; Teruya T; Urabe M; Mizukami H; Kume A; Nakamura M; Mineno J; Takesako K; Riviere I; Sadelain M; Brentjens R; Ozawa K
Biochem Biophys Res Commun; 2013 Aug; 438(1):84-9. PubMed ID: 23872144
[TBL] [Abstract][Full Text] [Related]
30. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
32. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
[TBL] [Abstract][Full Text] [Related]
33. [An experimental study of CD4 targeted chimeric antigen receptor modified T cell with anti-lymphoma activity].
Chen GH; Huang HW; Wang Y; Liu HW; Xu LJ; Ma X; Xue SL; He XF; Wang Y; Gu B; Li CX; Qiu HY; Tang XW; Jin ZM; Miao M; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):148-152. PubMed ID: 29562451
[No Abstract] [Full Text] [Related]
34. Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.
Panjwani MK; Smith JB; Schutsky K; Gnanandarajah J; O'Connor CM; Powell DJ; Mason NJ
Mol Ther; 2016 Sep; 24(9):1602-14. PubMed ID: 27401141
[TBL] [Abstract][Full Text] [Related]
35. T cells redirected against Igβ for the immunotherapy of B cell lymphoma.
Jiang D; Tian X; Bian X; Zhu T; Qin H; Zhang R; Xu Y; Pan Z; Huang H; Fu J; Wu D; Chu J
Leukemia; 2020 Mar; 34(3):821-830. PubMed ID: 31624374
[TBL] [Abstract][Full Text] [Related]
36. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
37. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.
Bastos-Oreiro M; Gutierrez A; Iacoboni G; López Corral L; Reguera JL; Abrisqueta P; Delgado J; Terol MJ; Hernani R; Martínez N; Ortíz V; Bailen R; Gomez-Centurión I; Caballero A; Sanz J; Guerra Domínguez L; Luzardo H; Mussetti A; Jiménez-Ubieto A; Sancho JM; Sureda A; Pérez A; Barba P; Kwon M; Martín García-Sancho A
Transplant Cell Ther; 2023 Dec; 29(12):747.e1-747.e10. PubMed ID: 37659694
[TBL] [Abstract][Full Text] [Related]
38. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
39. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
Sakai O; Igase M; Mizuno T
Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214
[TBL] [Abstract][Full Text] [Related]
40. In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles.
Zhao G; Zhang Y; Xu CF; Wang J
Sci Bull (Beijing); 2024 Feb; 69(3):354-366. PubMed ID: 38072706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
